The UK’s first fully NHS-embedded commercial research for brain and mental health conditions has been launched by Clerkenwell Health.  

Developed in partnership with Rotherham Doncaster and South Humber (RDaSH) NHS Foundation Trust, the initiative aims to set a new standard for how trials are delivered in the UK’s most pressing area of unmet health need.  

Clerkenwell state that the Doncaster site can act as a working prototype for how the UK can address long-standing barriers to brain and mental health research. The site will provide NHS patients will earlier access to investigational treatments and aims to reduce delays that have deterred global sponsors from conducting trials in the UK. 

Mental health is a great unmet need in the UK. Deaths related to drugs, alcohol or suicide have risen by 24% since the Covid-19 pandemic and 13-15% of working-age adults live with a long-term mental health or behavioural condition. Access to treatments however remains limited. Only 23% of primary care doctors are able to identify mental health trials in their region.  

Despite the urgency, domestic infrastructure for mental health trials has historically lagged behind. On average, NHS clinical trials take 250 days to set up, compared to 150 days in the US. Clerkenwell says its model is designed to cut this figure significantly – supporting the Government’s ambition to reduce set-up times and positioning the UK as a global leader in mental health innovation. 

Dr Henry Fisher, Chief Scientific Officer at Clerkenwell Health, said: “This site is a vital first step in giving the NHS the capacity and expertise to make clinical trials more accessible for mental health patients. By combining public and private strengths, our model removes referral barriers, raises clinician awareness, and streamlines patient access. Clerkenwell brings deep regulatory expertise, enabling the NHS to focus on what it does best – delivering outstanding patient care.”

Reece Armstrong, Editor, DDW